INCY acquires Escient Pharmaceuticals for $750 million

INCY announced that it will acquire Escient Pharmaceuticals, which has multiple high-potential differentiated and first-in-class drug pipelines, for $750 million. This acquisition will provide a strong complement to INCY's product portfolio and meet the needs of more patients.